source
- Zydus’ Sentynl pens $475M deal for Mereo’s phase 3-ready rare genetic lung disease drugSentynl Therapeutics has penned a deal potentially worth $475 million for the option to market Mereo BioPharma's phase 3-ready rare genetic respiratory disease drug in the U.S.Fierce Biotech · 5h ago↗ source
- Aura lays off 20% of workforce, rejigs C-suite amid R&D refocus on eye cancerAura Biosciences is refocusing under its recently installed CEO, laying off 20% of its employees and overhauling its C-suite as it narrows its focus on ocular oncology.Fierce Biotech · 6h ago↗ source
- Abbott teams with Google Health on AI-powered health insights appTwo giants of their respective fields, Abbott and Google, are joining forces for a first-of-its-kind team-up that aims to build out a digital picture of people’s health.